Hepatitis C after simultaneous liver–kidney transplantation  by Cerny, Andreas
www.elsevier.com/locate/jhep
Journal of Hepatology 51 (2009) 839–841Editorial
Hepatitis C after simultaneous liver–kidney transplantationq
Andreas Cerny*
Clinic for Internal Medicine, Liver Clinic, Clinica Luganese, Moncucco Hospital, Via Moncucco 10, 6900 Lugano, SwitzerlandSee Article, pages 874–880The introduction of the MELD score for organ allo-
cation in liver transplantation led to an increased
emphasis on renal impairment and to a proliferation
of simultaneous liver–kidney transplantation (SLK).
While the discussion on criteria is ongoing, information
on the natural history and management of recurrent
hepatitis C in this situation is lacking and consists
mostly of small retrospective reports based on the expe-
rience of single centers.
The study appearing in this issue by Van Wagner
et al. [1] reports the outcome of recurrent hepatitis C
after SLK in 38 patients at the Northwestern Univer-
sity Transplantation Center. Thirty-eight hepatitis C
virus (HCV)-positive patients undergoing liver trans-
plantation alone (LTA) in the same year serve as con-
trols. The design is retrospective, involving all SLK
patients transplanted between June 1999 and 2006.
The median time of observation after transplant was
34 months in the SLK group and 41 months in the
LTA group. Recurrence rates were somewhat higher
in LTA patients but there was no signiﬁcant diﬀerence
with respect to long-term patient and graft survival,
time to hepatitis C recurrence, percent >stage 2 ﬁbro-
sis, renal function and graft function between the two
groups. Treatment with pegylated interferon-alpha
(PEG-IFN-alpha) and ribavirin was attempted in ten0168-8278/$36.00  2009 European Association for the Study of the Liver.
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was achieved in 2 patients. Five patients had to stop
treatment due to side eﬀects and three had no response.
There were no kidney rejection episodes attributable to
the antiviral treatment.
As a bonus the study also oﬀers an important insight
into the practice and outcome of SLK in a period of
transition from pre-MELD to MELD-based organ allo-
cation. SLK patients with higher pre-transplant MELD
scores, have longer hospital stays, more infectious com-
plications and reduced 1-year survival of 73.7% as com-
pared to 91.9% in the LTA group (p = 0.029). After one
year Kaplan–Meyer curves continue in a more parallel
fashion. Of note is the ﬁnding that all 5 patients receiv-
ing expanded criteria donor (ECD) kidneys in combina-
tion with the liver died. The reader has to be cautioned,
however, that the study does not allow comparison of
the outcome of SLK in the presence or absence of hep-
atitis C, since no appropriate control group (HCV-neg-
ative SLK) was studied.
This is the largest study on SLK and recurrent HCV
and is also the largest account of treatment of recurrent
HCV in SLK. The main conclusion that can be drawn
from this paper is that treatment after SLK is feasible
and safe since there was no case of a kidney rejection
episode. The median follow-up period was reasonably
long with a median of almost three years and did not
suggest clear diﬀerences in the natural history of hepati-
tis C after SLK as compared to LTA. The treatment
outcome cannot be compared due to important diﬀer-
ences in genotype distribution.
Limitations of the study include its retrospective
design, the lack of uniform indications for SLK (20
out of 38 patients had hepato-renal syndrome before
transplant which today would not be considered to bePublished by Elsevier B.V. All rights reserved.
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choice of LTA patients as a control group which were
less sick before transplant (their median MELD score
was 17.4 versus 38 in the SLK group). The inclusion
of a control group consisting of LTA patients matched
for their MELD score would have been of interest.
The real frequency of recurrent hepatitis C may have
been underestimated in the SLK group since fewer liver
biopsies were performed, possibly due to reluctance to
treat recurrent hepatitis because of the risk of kidney
rejection.
In renal transplantation the use of interferon-based
treatments is usually discouraged due to the frequent
observation of acute rejection seen in older [2] and more
recent studies [3] and estimated to be in the 17–100 per-
cent range.
Treatment of recurrent hepatitis C with PEG-IFN-
alpha and ribavirin in SLK has been described in the
past by Schmitz et al. reporting on their experience with
6 patients (5 with genotype 1 and one with genotype 4)
using PEG-IFN-alpha2b (1 lg/kg/week) and ribavirin
(600 mg) for 48 weeks. SVR was achieved in 3/6 (50%)
patients. None of the patients developed signs of deteri-
orating kidney function or rejection. One patient with-
out SVR had HCV-related liver graft failure and died
13 months later. Neutropenia (50%) and anemia (50%)
were treated with G-CSF and erythropoietin [4].
Several factors have in the past been implicated to
have an eﬀect on the outcome of recurrent hepatitis C
in the post-transplant period, most importantly the exis-
tence of obesity, diabetes and hyperinsulinemia, rapid
taper steroid protocols, the choice of calcineurin inhibi-
tor, antiviral treatment, pre-OLT MELD score and the
origin of the organ of living versus deceased donors as
well as the intensity of immunosuppression, especially
steroid boluses, concomitant CMV infection, age of
the donor and steatosis of the graft [5–9].
An increased prevalence of glucose metabolism
abnormalities in HCV-infected patients was described
several years ago in the non-transplant population
[10]. The mechanism involves the interaction of HCV
with cellular pathways including the insulin signaling
cascade as well as intrahepatic inﬂammation and oxida-
tive stress via TNF-alpha. Some eﬀects were genotype-
dependent and are the topic of active research reviewed
recently elsewhere [11].
The Bermuda triangle of graft loss consisting of insu-
lin-resistance, HCV and immunosuppressive drugs is
addressed by another recently published study from
the Mount Sinai Medical Center by del Pozo et al.
reporting on 23 HCV-positive SLK transplants as com-
pared to HCV-negative controls and HCV-positive LTA
patients [12]. In that study post-transplant diabetes
occurred in 80% of the HCV-positive group as com-
pared to 30% of the HCV-negative group (p = 0.01).
However, overall patient survival for HCV-positiveand negative SLK and HCV-positive OLT groups at
1, 2, and 5 years were not signiﬁcantly diﬀerent. The
study by Van Wagner et al. does not report post-trans-
plant diabetes and we are left not knowing whether it
was not observed or simply not reported.
What can we learn from recent data on recurrent hep-
atitis C after SLK:
 Recurrent hepatitis C after SLK runs a similar course
to hepatitis C after LTA and HCV-positive recipients
should not be excluded as recipients for SLK.
 Recurrent hepatitis C needs to be diagnosed and trea-
ted with PEG-IFN-alpha and ribavirin, using growth
factors if necessary, to save the graft in case of severe
recurrence.
 The Northwestern University experience would sug-
gest to exclude ECD kidneys from SLK and to oﬀer
them to selected kidney transplant recipients.
 Treatment with PEG-IFN-alpha and ribavirin is pos-
sible and should be attempted since it cures a signiﬁ-
cant fraction of patients without elevated risks for the
kidney graft.
 It is tempting to speculate that the combined trans-
plantation of kidney and liver may protect the kidney
graft against acute rejection induced by PEG-IFN-
alpha treatment.
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